Objective To investigate the eBcacy and safety of toltero-of incontinence and pad use were reduced by 20%, 46% and 29%, respectively, while the volume at first dine, a new antimuscarinic agent, and define the optimum dosage in patients with symptoms of detrusor contraction increased by 89 mL. The 4 mg dosage was associated with a large increase in residual urinary instability (urgency, increased frequency of micturition and/or urge incontinence).volume and an increased incidence of dry mouth. The incidence of adverse events (mainly mild or moderate Patients and methods A double-blind, placebocontrolled, multicentre study was carried out; after a antimuscarinic eCects) was comparable with placebo at tolterodine dosages of∏2 mg. No serious adverse 1-week run-in period to establish baseline values, 81 patients were randomized to receive placebo or toltero-events were observed and tolterodine had no clinically significant impact on electrocardiographic or labora-dine 0.5, 1, 2 or 4 mg twice daily for 2 weeks. Micturition (diary) variables, urodynamics and subjec-tory findings. Conclusion The results indicate that tolterodine oCers tive urinary symptoms were assessed after 2 weeks' treatment.an eCective treatment for the symptoms of detrusor instability. The optimum dosage appears to be 1-2 mg Results A per-protocol analysis of eBcacy in 64 patients showed dose-related improvements in recorded mictur-twice daily. Keywords Tolterodine, antimuscarinic agents, detrusor ition and urodynamic variables, e.g. at a dosage of 2 mg twice daily, the frequency of micturition, episodes instability, dose-ranging study of urge incontinence and other symptoms of an over-